-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Alvotech (NYSE:ALVO) Trading Down 0.4%
Alvotech (NYSE:ALVO) Trading Down 0.4%
Alvotech (NYSE:ALVO – Get Rating)'s share price traded down 0.4% on Wednesday . The stock traded as low as $12.28 and last traded at $12.35. 77,686 shares were traded during mid-day trading, a decline of 66% from the average session volume of 225,790 shares. The stock had previously closed at $12.40.
Alvotech Stock Down 0.4 %
The firm's fifty day moving average price is $8.49 and its 200 day moving average price is $7.74.
Get Alvotech alerts:Institutional Investors Weigh In On Alvotech
A number of hedge funds have recently added to or reduced their stakes in the business. Jane Street Group LLC acquired a new stake in Alvotech during the 2nd quarter worth approximately $337,000. Millennium Management LLC acquired a new stake in Alvotech during the 2nd quarter worth approximately $431,000. Gamco Investors INC. ET AL acquired a new stake in Alvotech during the 2nd quarter worth approximately $110,000. Sculptor Capital LP acquired a new stake in Alvotech during the 2nd quarter worth approximately $6,612,000. Finally, UBS Group AG acquired a new stake in shares of Alvotech in the 2nd quarter valued at $112,000. 62.50% of the stock is currently owned by institutional investors and hedge funds.
About Alvotech
(Get Rating)Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.
Read More
- Get a free copy of the StockNews.com research report on Alvotech (ALVO)
- Procter & Gamble Earnings: A Gamble Worth Taking
- Stocks Slide, Economic Report Paints Gloomy Picture For Economy
- What does Nu Holdings Stock Have To Do With Warren Buffett?
- J.B. Hunt Gets A Flat, Logistic Companies Come Into Focus
- Is Intel Stock On The Verge Of Breaking Out?
Receive News & Ratings for Alvotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alvotech and related companies with MarketBeat.com's FREE daily email newsletter.
Alvotech (NYSE:ALVO – Get Rating)'s share price traded down 0.4% on Wednesday . The stock traded as low as $12.28 and last traded at $12.35. 77,686 shares were traded during mid-day trading, a decline of 66% from the average session volume of 225,790 shares. The stock had previously closed at $12.40.
艾沃科技(紐約證交所代碼:ALVO — 獲取評級)的股價在星期三下跌了 0.4%。該股票的交易價格低至 12.28 美元,最後交易價為 12.35 美元。中間交易期間有 77,686 股,較 225,790 股平均交易量下跌 66%。該股票之前已收盤 12.40 美元。
Alvotech Stock Down 0.4 %
艾沃科技股票下跌 0.4%
The firm's fifty day moving average price is $8.49 and its 200 day moving average price is $7.74.
該公司的五十天移動平均價格為 8.49 美元,其 200 日移動平均價格為 7.74 美元。
Institutional Investors Weigh In On Alvotech
機構投資者權衡艾沃科技
A number of hedge funds have recently added to or reduced their stakes in the business. Jane Street Group LLC acquired a new stake in Alvotech during the 2nd quarter worth approximately $337,000. Millennium Management LLC acquired a new stake in Alvotech during the 2nd quarter worth approximately $431,000. Gamco Investors INC. ET AL acquired a new stake in Alvotech during the 2nd quarter worth approximately $110,000. Sculptor Capital LP acquired a new stake in Alvotech during the 2nd quarter worth approximately $6,612,000. Finally, UBS Group AG acquired a new stake in shares of Alvotech in the 2nd quarter valued at $112,000. 62.50% of the stock is currently owned by institutional investors and hedge funds.
一些對沖基金最近增加或減少了他們在業務中的賭注。簡街集團有限責任公司在第二季度收購了艾沃科技的新股份,價值約為 337,000 美元。千禧管理有限責任公司在第二季度收購了艾沃科技的新股份,價值約為 431,000 美元。金高投資股份有限公司ET AL 在第二季度收購了艾沃科技的新股份,價值約為 110,000 美元。雕塑家資本 LP 在第二季度收購了艾沃科技的新股份,價值約為 6,612,000 美元。最後,瑞銀集團股份公司在第二季度收購了 Alvotech 股份的新股份,價值為 112,000 美元。目前,該股票的 62.50% 由機構投資者和對沖基金擁有。
About Alvotech
關於艾沃科技
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.
Alvotech 通過其子公司為全球患者開發和製造生物仿製藥物。它在自身免疫,眼睛和骨骼疾病以及癌症的治療領域提供生物仿製產品。該公司的主導計劃是 AVT02,一種高濃度的生物仿製劑,用於治療各種炎症狀,包括類風濕關節炎,牛皮癬關節炎,克羅恩病,潰瘍性結腸炎,斑塊性牛皮癬和其他適應症;AVT04,與 Stelara 生物類似物治療包括牛皮癬關節炎,克羅恩病,潰瘍性牙菌膜炎和其他適應症;是一種生物類似物治療,包括牛皮癬關節炎,克羅恩病,潰瘍性牙菌膜炎,其他適應症;AVT06, 生物類似於 Eylea 治療各種條件, 如與年齡相關的黃斑變性, 黃斑水腫, 和糖尿病視網膜病變;和 AVT03,Xgeva 和 Prolia 的一種生物仿製藥,它處於臨床前階段,用於治療預防骨折,脊髓壓縮以及對某些類型癌症患者進行放射或骨手術的需要,以及預防骨質流失和增加骨量。
Read More
閱讀更多
- Get a free copy of the StockNews.com research report on Alvotech (ALVO)
- Procter & Gamble Earnings: A Gamble Worth Taking
- Stocks Slide, Economic Report Paints Gloomy Picture For Economy
- What does Nu Holdings Stock Have To Do With Warren Buffett?
- J.B. Hunt Gets A Flat, Logistic Companies Come Into Focus
- Is Intel Stock On The Verge Of Breaking Out?
- 獲取有關艾沃特科技研究報告的免費副本
- 寶潔公司的收益:值得參加的賭博
- 股票幻燈片,經濟報告描繪經濟陰沉的圖片
- NU 控股股票與沃倫·巴菲特有什麼關係?
- J.B. 亨特得到一個單位, 物流公司成為焦點
- 英特爾股票是否瀕臨爆發?
Receive News & Ratings for Alvotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alvotech and related companies with MarketBeat.com's FREE daily email newsletter.
接收艾沃泰日報的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Alvotech 和相關公司的最新新聞和分析師評級的簡要每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧